Anagenics Signs Midkine Antibody Licencing Deal With Roquefort Therapeutics

Health and beauty company Anagenics (ASX:AN1) entered into a licensing agreement with Roquefort Therapeutics for its midkine intellectual property portfolio, according to a Friday filing with the Aust

MT NewswiresMay 24 05:49 ET

Anagenics Appoints CEO

Health and beauty company Anagenics (ASX:AN1) appointed Karen Matthews as chief executive, effective Friday, to succeed Scott Greasley. Matthews has extensive experience in the beauty industry, includ

MT NewswiresMar 7 21:51 ET

Anagenics Completes Placement to Raise AU$1.3 Million

Anagenics (ASX:AN1) completed a two-tranche placement of new fully paid ordinary shares to raise AU$1.3 million, before costs, the health and beauty technology company said Wednesday. The shares were

MT NewswiresFeb 6 21:47 ET

Anagenics Grows Fiscal H1 Revenue

Anagenics (ASX:AN1) reported total revenue for the fiscal first half of 2024 of AU$6.2 million, up from AU$5.3 million a year earlier. The health and beauty technology company narrowed its loss before

MT NewswiresJan 30 23:41 ET

Anagenics Acquires Face Medi Group

Anagenics (ASX:AN1) completed the acquisition of professional skincare and beauty retailer Face Medi Group, the health and beauty technology company said Monday. The company did not disclose the finan

MT NewswiresOct 2, 2023 06:19 ET